RxDoctor Payments DataLook up a doctor →

Theresa Lawrence Ford, MD

Rheumatology · Lawrenceville, GANPI 1619935624

Payments from drug & device makers

$2,894,243in general payments, 2019–2025

Across 1,681 payments — averaging $1721.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$535K
  • Novartis$464K
  • Amgen$449K
  • Eli Lilly$325K
  • Janssen Research & Development, LLC$231K
  • AbbVie$227K
  • plus $663K from 37 others
$4,038in research payments, 2019–2025

Across 5 payments — averaging $807.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$4K

What the payments were for

  • Consulting fees$33,9938%
  • Speaking & faculty fees$291,02571%
  • Travel & lodging$57,53814%
  • Food & beverage$27,2897%
  • Education$3890%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,894,243 in reported general payments places this provider in the 95th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia

Medicare billing

Part B allowed, 2024
$69,487
Medicare patients
180
Services billed
983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept80$664,261
RinvoqUpadacitinib88$643,045
Humira(Cf) PenAdalimumab61$629,782
Orencia ClickjectAbatacept62$368,607
Humira(Cf)Adalimumab27$184,419
Cosentyx Sensoready (2 Pens)Secukinumab22$179,913
OtezlaApremilast25$116,118
EnbrelEtanercept14$108,278
Simponi AriaGolimumab12$98,093
Humira PenAdalimumab11$87,221
Enbrel MiniEtanercept11$80,880
Actemra ActpenTocilizumab19$74,613
BenlystaBelimumab13$69,869
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$41,536
ProliaDenosumab23$39,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$227,260$827,464115 claims
AmgenOtezla, Enbrel, Prolia$449,317$263,61062 claims
Johnson & JohnsonSimponi Aria$5,224$98,09312 claims
GSKBenlysta$30,770$69,86913 claims
Grifols USA, LLCGamunex-C$66$41,53612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 rheumatology providers in Georgia.

Other rheumatology in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →